Posted in | News | Biomaterials

Amedica's FDA 510(k)-Cleared Devices Feature Expanded Biomaterials Claims

The data published in the journals, International Journal of Nanomedicine and Acta Biomaterialia have facilitated the expansion of biomaterials claim of the FDA 510(k)-cleared Valeo Interbody Fusion Devices developed by Amedica.

The articles elucidate the superior performance of silicon nitride-based interbody fusion devices in osteointegration and new bone formation in comparison to devices made from titanium or poly-ether-ether-ketone (PEEK). The additional benefit of these silicon nitride-based devices is their anti-infective properties. These inherent properties of Amedica’s proprietary biomaterial derived from silicon nitride form the crux of the biomaterials claim expansion. The claim expansion for Amedica’s Valeo Interbody Fusion Devices will form the basis for the development of standard of care for patients requiring spinal fusion for their back problems.

Physicians and health care providers are now aware of the properties of PEEK and titanium which have become the common source for biomaterials used in spinal devices. The studies published in the two journals describe the adverse effects of PEEK and titanium-based devices on patient outcomes. The materials have a tendency to develop a biofilm around the implant which significantly hinders bone formation. The latest changes to federal reimbursement for Medicaid and Medicare patients have strengthened the focus of the U.S. Congress on measures facilitating quality patient outcome. These developments have turned the spotlight on biomaterials for use in spinal and orthopedic implants.

Silicon Nitride has demonstrated great potential as an implant material. The effectiveness of the material has been validated by four years of successful application in interbody fusion devices.

Source: http://www.amedica.com/

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

G.P. Thomas

Written by

G.P. Thomas

Gary graduated from the University of Manchester with a first-class honours degree in Geochemistry and a Masters in Earth Sciences. After working in the Australian mining industry, Gary decided to hang up his geology boots and turn his hand to writing. When he isn't developing topical and informative content, Gary can usually be found playing his beloved guitar, or watching Aston Villa FC snatch defeat from the jaws of victory.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, G.P.. (2019, February 09). Amedica's FDA 510(k)-Cleared Devices Feature Expanded Biomaterials Claims. AZoM. Retrieved on April 24, 2024 from https://www.azom.com/news.aspx?newsID=34121.

  • MLA

    Thomas, G.P.. "Amedica's FDA 510(k)-Cleared Devices Feature Expanded Biomaterials Claims". AZoM. 24 April 2024. <https://www.azom.com/news.aspx?newsID=34121>.

  • Chicago

    Thomas, G.P.. "Amedica's FDA 510(k)-Cleared Devices Feature Expanded Biomaterials Claims". AZoM. https://www.azom.com/news.aspx?newsID=34121. (accessed April 24, 2024).

  • Harvard

    Thomas, G.P.. 2019. Amedica's FDA 510(k)-Cleared Devices Feature Expanded Biomaterials Claims. AZoM, viewed 24 April 2024, https://www.azom.com/news.aspx?newsID=34121.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.